Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results for the first quarter ended March 31, 2024. The pharmaceutical company specializing in precision-based cannabinoids revealed a revenue increase of 67% to $9.8 million versus revenue for the same quarter in 2023 of $5.8 million.
MediPharm Labs Corp.（多倫多證券交易所股票代碼：LABS）（OTCQB: MEDIF）（FSE: MLZ）公佈了截至2024年3月31日的第一季度財務業績。這家專門生產精密大麻素的製藥公司透露，收入增長了67％，達到980萬美元，而2023年同期的收入爲580萬美元。
"This quarter shows another quarter of growing revenue, stronger gross profit, decreasing costs and improving Adjusted EBITDA," stated David Pidduck, CEO. "MediPharm's balance sheet is in an excellent position to consider future investments in growth. With Adjusted EBITDA getting close to breakeven, the leadership team can now devote even more energy to growing our business. Regulatory changes in Germany and Australia and potential upcoming changes in the US are all very favorable for the company."
首席執行官戴維·皮德杜克表示：“本季度收入又增長了一個季度，毛利潤增強，成本下降和調整後息稅折舊攤銷前利潤有所改善。”“MediPharm的資產負債表非常適合考慮未來的增長投資。隨着調整後的息稅折舊攤銷前利潤接近盈虧平衡，領導團隊現在可以投入更多精力來發展我們的業務。德國和澳大利亞的監管變化以及美國即將發生的潛在變化都對公司非常有利。”
More about investments and financial data from the industry you can hear at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.
您可以在10月8日至9日在芝加哥舉行的第19屆Benzinga大麻資本會議上聽到有關該行業投資和財務數據的更多信息。與高層管理人員、投資者、政策制定者和倡導者互動，探索該行業的未來。在價格上漲之前，立即通過以下方式保護您的門票 這個鏈接。
Q1 Financial Summary
第一季度財務摘要
- Gross profit was $2.7 million or 27% which improved significantly versus the first quarter 2023 gross profit of 6.6% and versus the fourth quarter of last year of 24.3%.
- Adjusted EBITDA improved 70% to a loss of $900,000 from a loss of $3.1 million in the same period of 2023, and improved sequentially from a loss of $1.6 million in the prior quarter.
- Net loss amounted to $3.6 million, compared to a loss of $3.09 million in the same period of last year.
- As of March, 31, 2023 the company reported a balance sheet with $17 million in cash and less than $3 million in debt.
- 毛利爲270萬美元，增長27％，與2023年第一季度的6.6％和去年第四季度的24.3％相比顯著改善。
- 調整後的息稅折舊攤銷前利潤從2023年同期的310萬美元虧損增長了70％，至虧損90萬美元，並從上一季度的160萬美元虧損連續增長。
- 淨虧損爲360萬美元，而去年同期的虧損爲309萬美元。
- 截至2023年3月31日，該公司公佈的資產負債表中現金爲1,700萬美元，債務不到300萬美元。
Greg Hunter, CFO, MediPharm Labs added, "Q1 2024 was another step in the right direction towards profitability and becoming cash flow positive. Our revenue and Adjusted EBITDA were both the highest in over 3 years. Revenue was $9.8 million or 67% higher than the prior year and Adjusted EBITDA loss was $0.9 million which is $2.1 million better than the prior year. Our cash burn was approximately $1 million resulting in an ending cash balance of $17 million with less than $3 million of debt. MediPharm is in a strong financial position to capitalize on our strong suite of licenses, global customer contracts and assets as we strive for profitability in 2024."
MediPharm Labs首席財務官格雷格·亨特補充說：“2024年第一季度是朝着盈利和現金流爲正的正確方向邁出的又一步。我們的收入和調整後的息稅折舊攤銷前利潤均爲3年多來的最高水平。收入爲980萬美元，比上年增長67％，調整後的息稅折舊攤銷前利潤虧損爲90萬美元，比上年增長210萬美元。我們的現金消耗約爲100萬美元，期末現金餘額爲1700萬美元，債務不到300萬美元。MediPharm的財務狀況良好，可以利用我們強大的許可證、全球客戶合同和資產，努力在2024年實現盈利。”
The company said it anticipates further improvement in profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1 million to $2 million, which plans include the ongoing optimization of production and logistics facilities.
該公司表示，預計2024年盈利能力將進一步提高，並計劃將調整後的息稅折舊攤銷前利潤再提高100萬至200萬美元，其中包括持續優化生產和物流設施。
Price Action
價格走勢
MediPharm Labs shares traded flat at $26.44 per share during Wednesday's pre-market session.
在週三的盤前交易中，MediPharm Labs的股價持平至每股26.44美元。
Photo: Courtesy of Branding Pot via Shutterstock
照片：由 Branding Pot 通過 Shutterstock 提供
譯文內容由第三人軟體翻譯。